{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["61(8)"],"submitter":["Cohen S"],"pubmed_abstract":["<h4>Background</h4>There are scarce data available on upadacitinib in children with Crohn's disease (CD).<h4>Aim</h4>To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD.<h4>Methods</h4>This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post-induction. The analysis of the primary outcome was based upon the intention-to-treat (ITT) principle.<h4>Results</h4>We included 100 children (median age 15.8 [interquartile range 14.3-17.2]). All were previously treated with biologi"],"journal":["Alimentary pharmacology & therapeutics"],"pagination":["1372-1380"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11950809"],"repository":["biostudies-literature"],"pubmed_title":["Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study."],"pmcid":["PMC11950809"],"pubmed_authors":["Urlep D","Uhlig HH","Granot M","Yerushalmy-Feler A","Wlazlo M","Yogev D","Henderson P","Hradsky O","Hojsak I","Turner D","Rinawi F","Mitrova K","Kang B","Shouval DS","Olbjorn C","Hackl L","Sansotta N","Tzivinikos C","Suskind DL","Trindade E","Spencer EA","Conrad MA","Norsa L","Pujol-Muncunill G","Cohen S","Kolho KL","Scarallo L","Rodriguez-Belvis MV","Rungoe C","Bramuzzo M","Gasparetto M","D'Arcangelo G","Rimon RM","Dolinger MT","Kelsen JR"],"additional_accession":[]},"is_claimable":false,"name":"Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study.","description":"<h4>Background</h4>There are scarce data available on upadacitinib in children with Crohn's disease (CD).<h4>Aim</h4>To evaluate the effectiveness and safety of upadacitinib as an induction therapy in paediatric CD.<h4>Methods</h4>This was a multicentre retrospective study between 2022 and 2024 of children treated with upadacitinib for induction of remission of active CD conducted in 30 centres worldwide affiliated with the IBD Interest and Porto group of the ESPGHAN. We recorded demographic, clinical and laboratory data and adverse events (AEs) at week 8 post-induction. The analysis of the primary outcome was based upon the intention-to-treat (ITT) principle.<h4>Results</h4>We included 100 children (median age 15.8 [interquartile range 14.3-17.2]). All were previously treated with biologi","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Apr","modification":"2025-06-25T03:04:31.718Z","creation":"2025-06-25T03:04:31.718Z"},"accession":"S-EPMC11950809","cross_references":{"pubmed":["39921898"],"doi":["10.1111/apt.70016"]}}